Kliniska studier vid Tema Cancer

Watch and wait. Watch and wait-Icke operativ behandling vid strål- och cellgiftsbehandling.

Anna Martling

PRORECT. Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT):A Prospective Randomized Swedish Phase II Trial

Alexander Valdman

CIM-HIPEC. The native immune system and the development of carcinomatosis among patients with colorectal cance

Caroline Nordenvall

CIM-IBD. Single-cell analysis of intestinal lymphocytes reveals targets for treatment of inflammatory bowel disease

Caroline Nordenvall

CITCCA pilot. CIrculating Tumour DNA in Colorectal CAncer, pilotstudie

Anna Martling

CRUISE. Restorative treatment with ileorectal anastomosis or ileal pouch anal anastomosis in patients with ulcerative colitis

Caroline Nordenvall

EFFIPEC. EFFIPEC – Efficacy of Hyperthermic Intraperitoneal ChemotherapySingle-arm Phase I study, followed by an open-label, randomized, controlled registry-based phase III trial

Gabriella Palmer

PelvEx II. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer

Henrik Iversen

HILOS. HIPEC and LOng of Stay - Patienters upplevelse och erfarenheter av högspecialiserad buk- och bäckencancerkirurgi

Tina Gustavell

SELSA. Selective defunstionen stoma approach in low anterior resection for rectal cancer(SELSA): a prospective study and a nested randomised clinical trial

Naseer Baloch

RACC. The RACC trial -Robot Assisted Approach to Cervical Cancer

Henrik Falconer

SCAN-Mi-studien-cervix. Mikrobiomets associerade biomarkörers betydelse för utveckling och prognos av livmoderhals- och huvudhals-cancer.

Henrik Falconer

TITANIUM. GestaTIonal TrophoblAstic NeoplasIa assessMent

Ulrika Joneborg

GeMore-studien. Genetisk och molekylär kartläggning samt riktad behandling inom gynekologisk cancer

Josefin Fernebro

ISGA-studien (pre-GAT01). studier av immunsystemet hos patienter med gyncancer

Emelie Wallin

ct-DNA-studien på cervixcancer. Analys av cell-fritt tumör-DNA i blod.

Kristina Hellman

PARP-PET. [11C]AZ14193391 - PET as a selection tool for treatment with PARP inhibitors in patients with metastatic solid tumors

Rimma Axelsson/ onk: Josefin Fernebro

FOLERO. Frailty, quality Of Life and Early Reversal of temporary defunctioning Stoma in Ovarian Cancer

Sahar Salehi, Daniel Hunde

MK-2870-005/ENGOT-en23. A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants with Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy

Magnus Frödin-Bolling

MK2870-020-Cervix. A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line or Third-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (MK-2870-020/GOG-3101/ENGOT-Cx20)

Kristina Hellman

SPCG-15. Primary radical prostatectomy versus primary radiotherapy for locally advanced prostate cancer: an open randomized clinical trial

Mats Olsson

PSMA recidiv-studien. En randomiserad jämförelse mellan konventionell "Salvage" strålbehandling och individualiserad PSMA-pet styrd behandling hos patienter med biokemiskt återfall (PSA) efter prostatacancer operation

Stefan Carlsson

ProBio . ProBio: An outcome-adaptive and randomized multi-arm biomarker driven study in patients with metastatic castrate resistant prostate cancer mCRPC)

Anders Ullén

MK3475-365. Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Enrique Castellanos

PRIS. Prostate Cancer IRE Study (PRIS) – A randomized controlled trial comparing focal to radical treatment in localized prostate cancer

Anna Lantz

METRO. Metastasis directed Stereotactic Body Radiotherapy (SBRT) for Oligo metastatic Hormone sensitive Prostate Cancer

Mattias Hedman

CAAA617A12402. Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer

Enrique Castellanos

OMAHA-003. A Phase 3 Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated with Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

Enrique Castellanos

OMAHA-004. A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA)

Anna Kristiansen

IPA. Incontinence Post robot assisted radical prostatectomy, Anatomical and functional causes

Stefan Carlsson

BioBladder. Biomarker profiling to predict response and survival in patients receiving systemic therapy for advanced urothelial cancer

Anders Ullén

RWD Avelumab. A Swedish nationwide real-world data study of maintenanceavelumab in patients with advanced urothelial cancer withoutprogression following first-line platinum-based chemotherapy

Faith Jawdat

SGNDV-001/KN-D74. An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2

Anders Ullén

V940-005-00-Blåsa. A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with High-Risk Muscle-Invasive Urothelial Carcinoma Post-Radical Resection

Anders Ullen

TINCA II - njurcancer. Det immunologiska landskapet i njurcancer

Ulrika Harmenberg